enVVeno Medical Corp Dossier - Source-backed chat

enVVeno Medical Corp

NVNONASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.03

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.80Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $5.4M

Enterprise Value $3.2M

Shares Outstanding 674K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

enVVeno Medical Corp is a clinical-stage medical device company focused on bioprosthetic solutions for deep venous disease. Following a major setback in late 2025 when the FDA issued an unfavorable appeal decision on its surgical VenoValve PMA, the company strategically pivoted to its next-generation, minimally invasive transcatheter enVVe System. In April 2026, enVVeno achieved a landmark milestone by receiving FDA IDE approval to initiate the TAVVE U.S. pivotal study. While the addressable market of 3 million severe deep chronic venous insufficiency (CVI) patients in the U.S. represents a multi-billion-dollar opportunity, the company remains pre-revenue and highly dependent on clinical execution. With approximately $24.9 million in cash and investments as of Q1 2026, the company has an operating runway into Q3 2027. Given the early stage of the TAVVE trial and the binary regulatory risks inherent in medical device development, a Hold recommendation is warranted until initial safety data from the first 10-patient cohort is established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$30.00

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The primary bear case for enVVeno Medical centers on regulatory and clinical execution risks. The FDA previously issued a 'not-approvable' letter for its surgical VenoValve device due to concerns over safety (rehospitalizations) and the lack of specific hemodynamic measurements to prove efficacy. Consequently, the company had to pivot entirely to its next-generation, non-surgical transcatheter device, enVVe. While enVVe received IDE approval in April 2026 to begin the TAVVE pivotal study, any clinical setbacks, safety issues, or failure to meet FDA endpoints would severely impact the company. Furthermore, enVVeno is pre-revenue, has a history of operating losses, and is projected to fund operations only into the third quarter of 2027 with its $25 million cash balance (as of March 31, 2026), exposing investors to potential dilution from future capital raises.

Base CaseCentral scenario

The TAVVE pivotal study successfully initiates clinical site activation and patient enrollment in late 2026. The initial 10-patient safety cohort completes its 30-day follow-up with no major adverse events, allowing the FDA to clear the transition to the 220-patient second stage. Cash burn remains managed within the projected $4.0 million to $5.0 million quarterly range, and the company selectively utilizes its ATM facility to maintain a comfortable cash runway beyond 2027.

Bull CaseUpside scenario

Successful execution of the TAVVE pivotal study leading to FDA approval of the enVVe transcatheter venous valve, unlocking a multi-billion-dollar untapped U.S. market of 3 million severe deep CVI patients with a first-mover advantage.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Landmark FDA IDE approval received in April 2026 for the TAVVE pivotal study of the enVVe transcatheter venous valve.
Large underserved target market of approximately 3 million U.S. patients suffering from severe deep chronic venous insufficiency (CVI).
Minimally invasive transcatheter delivery of enVVe requires no general anesthesia or overnight hospital stay, enhancing potential physician adoption.
Adequate near-term liquidity with $24.9 million in cash and investments as of March 31, 2026, providing an operating runway into Q3 2027.

Key Investment Risks

Pre-revenue financial profile with ongoing net losses ($3.8 million in Q1 2026) and high dependence on capital markets or dilutive ATM programs.
Clinical trial execution risks, including potential delays in clinical site activation, patient enrollment, or meeting safety/efficacy endpoints.
Binary regulatory risk, as highlighted by the previous unfavorable FDA appeal decision for the surgical VenoValve in late 2025.

Thesis Invalidation Triggers

Safety concerns or serious adverse events observed in the initial 10-patient cohort of the TAVVE study.
Failure or significant delay in obtaining FDA clearance to proceed to the second stage of the TAVVE study.
Quarterly cash burn accelerating significantly above $5.0 million, leading to premature balance sheet dilution.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.